Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: A study using 24-h dual-channel pH-metry

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 6, 2008, Pages 654-661

  Ghoshal, Uday C ^a   Chourasia, Dipti ^a   Tripathi, Shweta ^a   Misra, Asha ^a   Singh, Kartar ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acid secretion; Esophageal physiology; Esophagitis; Los Angeles classification; Proton pump inhibitor

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; CARLSSON DENT SCORE; DEMEESTER SCORE; DEMOGRAPHY; DISEASE SEVERITY; ESOPHAGITIS; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS MANOMETRY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PH MEASUREMENT; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STOMACH ACID SECRETION; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; DUODENOSCOPY; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMANS; MALE; MANOMETRY; MIDDLE AGED;

EID: 45749144041     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701864635     Document Type: Article

References (37)

1. Bennett JR. Aetiology, pathogenesis, and clinical manifestations of gastro-oesophageal reflux disease. Scand J Gastroenterol 1988; Suppl 146:67-72.
2. Cadiot G, Bruhat A, Rigaud D, Coste T, Vuagnat A, Benyedder Y, et al. Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut 1997;40:167-74.
3. Armstrong D. Review article: gastric pH: the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004;20 Suppl 5:19-26, discussion 38-9.
4. Bremner RM, Crookes PF, DeMeester TR, Peters JH, Stein HJ. Concentration of refluxed acid and esophageal mucosal injury. Am J Surg 1992;164:522-6, discussion 526-7.
5. Barlow AP, DeMeester TR, Ball CS, Eypasch EP. The significance of the gastric secretory state in gastroesophageal reflux disease. Arch Surg 1989;124:937-40.
6. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991;101:1149-58.
7. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990;98:654-61.
8. Collen MJ, Johnson DA, Sheridan MJ. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy. Dig Dis Sci 1994;39:410-7.
9. Gardner JD, Sloan S, Robinson M, Miner PB Jr. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor. Aliment Pharmacol Ther 2004;20:1381-6.
10. Irwin RS, French CL, Curley FJ, Zawacki JK, Bennett FM. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest 1993;104: 1511-7.
11. Klinkenberg-Knol EC, Meuwissen SG. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990;4:485-95.
12. Katz PO. Review article: Intragastric and esophageal pH monitoring in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 2006;23 Suppl 1:3-11.
13. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-7.
14. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545-50.
15. 2-RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32.
16. Regan PT, Malagelada JR, Dimagno EP, Go VL. Postprandial gastric function in pancreatic insufficiency. Gut 1979;20:249-54.
17. Kwiecien S, Konturek SJ. Gastric analysis with fractional test meals (ethanol, caffeine, and peptone meal), augmented histamine or pentagastrin tests, and gastric Ph recording. J Physiol Pharmacol 2003;54 Suppl 3:69-82.
18. Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-9.
19. Saraswat VA, Dhiman RK, Mishra A, Naik SR. Correlation of 24-h esophageal pH patterns with clinical features and endoscopy in gastroesophageal reflux disease. Dig Dis Sci 1994;39:199-205.
20. Bowrey DJ, Williams GT, Clark GW. Histological changes in the oesophageal squamous mucosa: correlation with ambulatory 24 hour pH monitoring. J Clin Pathol 2003;56:205-8.
21. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001;16:1191-6.
22. Jalal A, Payne HR, Jeyasingham K. The influence of age on gastro-oesophageal reflux: a re-appraisal of the DeMeester scoring system. Eur J Cardiothorac Surg 2000;18:411-7.
23. Freeland GR, Higgs RH, Castell DO, McGuigan JE. Lower esophageal sphincter and gastric acid response to intravenous infusions of synthetic human gastrin I heptadecapeptide. Gastroenterology 1976;71:570-4.
24. Corazziari E, Pozzessere C, Dani S, Anzini F, Torsoli A. Lower oesophageal sphincter response to intravenous infusions of pentagastrin in normal subjects, antrectomised and achalasic patients. Gut 1978;19:1121-4.
25. Kravitz JJ, Snape WJ Jr, Cohen S. Effect of histamine and histamine antagonists on human lower esophageal sphincter function. Gastroenterology 1978;74:435-40.
26. Bozymski EM. Pathophysiology and diagnosis of gastroesophageal reflux disease. Am J Hosp Pharm 1993;50:S4-6.
27. Achem AC, Achem SR, Stark ME, DeVault KR. Failure of esophageal peristalsis in older patients: association with esophageal acid exposure. Am J Gastroenterol 2003;98:35-9.
28. Wang H, Liu B. The relationship between lower esophageal sphincter motility and function with gastroesophageal reflux disease. Zhonghua Nei Ke Za Zhi 2004;43:750-2.
29. Richter J. Do we know the cause of reflux disease? Eur J Gastroenterol Hepatol 1999;11 Suppl 1:S3-9.
30. Kasapidis P, Xynos E, Mantides A, Chrysos E, Demonakou M, Nikolopoulos N, et al. Differences in manometry and 24-h ambulatory pH-metry between patients with and without endoscopic or histological esophagitis in gastroesophageal reflux disease. Am J Gastroenterol 1993;88:1893-9.
31. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-esophageal reflux disease. Aliment Pharmacol Ther 1999;13:49-57.
32. Castell DO. Nocturnal acid breakthrough in perspective: let's not throw out the baby with the bath water. Am J Gastroenterol 2003;98:517-8.
33. Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-31.
34. Katzka DA, Paoletti V, Leite L, Castell DO. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 1996;91:2110-13.
35. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
36. Katz PO, Anderson C, Khoury R, Castell DO. Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12:1231-4.
37. 2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351-6.